PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced

Status Not yet recruiting

Clinical Trial Summary

Evaluate the efficacy and safety of PD1 monoclonal antibody combined with mFOLFOX6 neoadjuvant therapy for advanced resectable metastatic colon cancer with enriched pro-inflammatory pan macrophage subpopulations

Clinical Trial Description

In this study, patients with advanced resectable metastatic colon cancer requiring neoadjuvant chemotherapy were selected, and colon cancer patients enriched with TNFSF10+CXCL10+ panTAMs subgroup were screened, and neoadjuvant chemotherapy was performed with PD-1 monoclonal antibody combined with chemotherapy. To evaluate the efficacy and safety of PD-1 monoclonal antibody combined with neoadjuvant chemotherapy in the treatment of special types of colon cancer. All patients in this study were examined in the tumor microenvironment before treatment, and only patients enriched with TNFSF10+CXCL10+ panTAMs subgroup were enrolled in the study. Due to the long detection time, the patient received mFOLFOX6 chemotherapy for one week in the first cycle. If the test results meet the enriched proinflammatory panmacrophage subpopulation, patients can eventually be enrolled and receive PD-1 monoclonal antibody (Serplulimab, Srulimab) combined with mFOLFOX6 (oxaliplatin, fluorouracil) regimen, 2 weeks for 1 cycle. The primary radical resection was performed after 5 cycles of neoadjuvant therapy. Local treatment of liver/lung metastases was performed at the same time or at different times. Continue mFOLFOX6 chemotherapy for 4-6 cycles or CAPEOX regimen for 4 cycles within 1-2 months after surgery. Liver and lung metastases allow local treatment in any of these treatment cycles, including but not limited to radiofrequency ablation, particle implantation, radiation therapy, and surgery. At the end of postoperative adjuvant therapy, NED status was achieved. Then, regular follow-up. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT06335147
Study type	Interventional
Source	Henan Cancer Hospital
Contact	Ning Li
Phone	0086-13526501903
Email	lining97@126.com
Status	Not yet recruiting
Phase	N/A
Start date	April 1, 2024
Completion date	January 31, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04186117` - Development of Clinical and Biological Database in Colorectal Cancer	N/A
Completed	`NCT05468892` - Phase II Randomized Study Evaluating the Efficacy of Panitumumab (VEctibix ) and Trifluridine-Tipiracil (LOnsurf) in Pretreated RAS Wild Type Metastatic Colorectal Cancer Patients: the VELO Trial	Phase 2
Recruiting	`NCT02291744` - A Phase Ⅱ Study of XELOX Chemotherapy With or Without Surgery of Primary Lesion for Colon Cancer Patients	Phase 2
Active, not recruiting	`NCT00986661` - A Study to Assess PV-10 Chemoablation of Cancer of the Liver	Phase 1
Completed	`NCT03176485` - Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors	N/A
Recruiting	`NCT05983367` - A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer	Phase 2
Recruiting	`NCT03730558` - ZETA : Prospective Observational Study
Recruiting	`NCT06180460` - CALM: Managing Distress in Malignant Brain Cancer	N/A
Active, not recruiting	`NCT03251378` - A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer	Phase 1
Recruiting	`NCT04737213` - SGM-101 in Colorectal Lung Metastases	Phase 2
Recruiting	`NCT05714124` - Liver Embolization Approaches for Tumor Management
Recruiting	`NCT05396807` - REVERT - taRgeted thErapy for adVanced colorEctal canceR paTients	N/A
Active, not recruiting	`NCT02724202` - Curcumin in Combination With 5FU for Colon Cancer	Early Phase 1
Withdrawn	`NCT03764137` - Imaging With [89Zr]Panitumumab-PET/MRI in Patients With Newly Diagnosed Colorectal Cancer	Phase 1/Phase 2
Recruiting	`NCT05848739` - A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors	Phase 1
Not yet recruiting	`NCT06202183` - Exercise for Gut Microbiome in Patients With Young-Onset Colorectal Cancer Undergoing Chemotherapy: The COURAGE Trial	N/A
Withdrawn	`NCT01936961` - Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors	N/A
Not yet recruiting	`NCT06358677` - Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Metastatic Colorectal Cancer	Phase 2
Completed	`NCT03415126` - A Study of ASN007 in Patients With Advanced Solid Tumors	Phase 1
Completed	`NCT02834052` - Pembrolizumab + Poly-ICLC in MRP Colon Cancer	Phase 1/Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms